XSWXEVE
Market cap6mUSD
Dec 20, Last price
0.81CHF
1D
-9.80%
1Q
-10.99%
Jan 2017
-99.47%
IPO
-99.97%
Name
Evolva Holding SA
Chart & Performance
Profile
Evolva Holding SA discovers, researches, develops, and commercializes nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. It offers various ingredients comprising Veri-te Resveratrol, a nature-made polyphenol that occurs naturally in grapes and other plants, including peanuts, cranberries, and berries; L-Arabinose, a flavoring agent used in Maillard reaction; Valencene, an aroma component of citrus fruit and citrus-derived odorants; Nootkatone, an aroma ingredient of grapefruit obtained via biochemical oxidation of valencene; and Vanillin, a primary component of vanilla bean extract. The company was founded in 2004 and is headquartered in Reinach, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 9,438 -39.27% | 15,539 57.32% | 9,878 30.99% | |||||||
Cost of revenue | 51,386 | 38,898 | 36,870 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (41,948) | (23,359) | (26,992) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 7,862 | (141) | ||||||||
Tax Rate | ||||||||||
NOPAT | (41,948) | (31,221) | (26,851) | |||||||
Net income | (105,229) 142.65% | (43,366) 5.09% | (41,266) 38.15% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,046 | 7,352 | ||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 12,151 | 7,265 | ||||||||
Long-term debt | 5,814 | 7,148 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,579 | 3,196 | 5,609 | |||||||
Net debt | (5,839) | 10,749 | 1,515 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (9,254) | (18,881) | (29,789) | |||||||
CAPEX | (2,253) | (3,784) | ||||||||
Cash from investing activities | 15,949 | (1,764) | (4,640) | |||||||
Cash from financing activities | (5,973) | 14,766 | 25,722 | |||||||
FCF | (19,512) | (34,400) | (36,874) | |||||||
Balance | ||||||||||
Cash | 5,839 | 5,143 | 11,001 | |||||||
Long term investments | 2,073 | 1,898 | ||||||||
Excess cash | 5,367 | 6,439 | 12,405 | |||||||
Stockholders' equity | 5,570 | (266,512) | (234,114) | |||||||
Invested Capital | 1,765 | 391,004 | 382,332 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 5,396 | 4,281 | 3,520 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (37,367) | (15,268) | (18,392) | |||||||
EV/EBITDA | ||||||||||
Interest | 2,291 | 761 | 983 | |||||||
Interest/NOPBT |